Skip to content

Baxter International BAX Non-Marketable Investment Impairment

Discontinued — last reported Q4 '25

Non-Marketable Investment Impairment at other companies

Citigroup logo
CitigroupC
$140M+141%
Evercore logo
EvercoreEVR
$2.03M
Dominion Energy logo
Dominion EnergyD
$291M-25.0%
Semtech logo
SemtechSMTC
$302.75K-96.0%
Semtech logo
SemtechSMTC
NRZ
New Residential Investment Corp.NRZ

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$10.27B-50.6%
Enterprise value$8.48B-55.6%
P/S0.9×-1.0×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept bax:NonMarketableInvestmentImpairment.

The official record: Baxter International’s 10-K, filed February 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Baxter International's non-marketable investment impairment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Baxter International's non-marketable investment impairment?
Baxter International (BAX) reported non-marketable investment impairment of $0 in Q4 2025.
What does non-marketable investment impairment mean?
Write-downs of private or non-traded investments due to loss of value.
How do you interpret non-marketable investment impairment?
Frequent or large impairments suggest poor due diligence or high-risk investment strategies in private markets.
How does non-marketable investment impairment compare across companies?
Common for companies with active corporate venture capital arms; peers in similar sectors will show varying levels of impairment.